Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

• Hauptverfasser: Frank van den Ouweland (VerfasserIn), Nicola Charpentier (VerfasserIn), Özlem Türeci (VerfasserIn), Ruben Rizzi (VerfasserIn), Federico J. Mensa (VerfasserIn), Claudia Lindemann (VerfasserIn), Shanti Pather (VerfasserIn)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

ABSTRACTThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to urgent actions by innovators, vaccine developers, regulators, and other stakeholders to ensure public access to protective vaccines while maintaining regulatory agency standards. Although development t...